THNR — Amplify Weight Loss Drug & Treatment ETF
Data updated: 2026-08-28
THNR — Amplify Weight Loss Drug & Treatment ETF. Global (incl. US) Large Cap Growth Materials Equity. Holdings, fees, performance and SEC filings.
THNR Fund Overview
THNR — Amplify Weight Loss Drug & Treatment ETF is a US ETF managed by Amplify ETF Trust, categorised as Global (incl. US) Large Cap Growth Materials Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: Amplify ETF Trust
- Category: Global (incl. US) Large Cap Growth Materials Equity
- Assets under management: $4.36M
- 1-year return: 15.2%
- Ticker: THNR
- SEC CIK: 0001633061
- SEC series ID: S000085024
- Share class ID: C000249887
THNR Investment Objective and Strategy
Amplify Weight Loss Drug & Treatment ETF describes its objective and strategy as follows, from its latest prospectus filed with the SEC by Amplify ETF Trust.
Investment objective
The Amplify Weight Loss Drug & Treatment ETF seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug & Treatment Index (the Index).
Principal investment strategy
The Fund invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the Index. VettaFi LLC, a wholly -owned subsidiary of TMX Group Limited developed and maintains the Index (the Index Provider). Amplify Investments LLC is the investment adviser to the Fund (Amplify or the Adviser) and Penserra Capital Management LLC serves as the investment sub -adviser to the Fund (Penserra or the Sub -Adviser ). The Fund will generally use a replication strategy to achieve its investment objective, meaning the Fund will generally invest in all of the component securities of the Index. However, the Fund may use a representative sampling strategy, meaning it may invest in a sample of the securities in the Index whose risk, return, and other characteristics closely resemble the risk, return, and other characteristics of the Index as a whole, when the Funds portfolio managers believe it is in the best interests of the Fund.
The Index includes common stocks and/or depositary receipts, such as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The Index Provider is not affiliated with the Fund, the Adviser, or the Sub -Adviser . The Index. The Index is comprised of global companies expected to economically benefit from weight loss drug development. The Index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP -1 agonists and analogs, including dual GLP -1 agonists and analogs. The Index begins with a universe of common stocks issued by companies located in developed and emerging market countries around the world deemed by the Index Provider to have sufficient access, liquidity and foreign exchange markets to support a funds foreign investment trading.
From this initial universe, to be eligible for inclusion in the Index, a company must have a market capitalization greater than or equal to $500 million and a three -month average daily trading volume of at least $1 million. The Index Provider will select twenty constituents to be included in the Index. The constituents must meet the requirements to be classified as a Weight Loss Drug Manufacturer, Combination Therapies Drug Manufacturer or a Telehealth Provider based on the following criteria: Weight Loss Drug Manufacturers are those companies with GLP -1 agonist, amylin agonists and analogs or dual agonist drugs that have either launched or are currently undergoing clinical trials with the Food and Drug Administration (FDA). The Weight Loss Drug Manufacturers are then further classified into three subsegments depending on the stage of development: commercial, phase 3 and phase 2 and lower.
Combination Therapies Drug Manufacturers are those companies with drugs that are either being marketed or undergoing FDA clinical trials for combination use with Amylin agonists and analogs or GLP -1 agonist and analogs, including dual GLP -1 agonists and analogs. Telehealth Providers are those companies who provide access to Amylin agonists and analogs or GLP -1 agonists and analogs, including dual GLP -1 agonists and analogs. Each resulting constituent selected for inclusion in the Index is defined as a Weight Loss Drug and Treatment Company. Under normal market conditions, the Fund will invest at least 80% of its net assets (plus any borrowings for investment purposes) in Weight Loss Drug and Treatment Companies. If more than twenty constituents are chosen, companies will be excluded in the following order until twenty constituents remain.
Companies with the lowest full market capitalizations that are not in the commercial stage or the phase 3 stage segments of the Weight Loss Drug Manufactures segment are first excluded. Following, companies with the lowest full market capitalizations that are in the commercial stage or the phase 3 stage segments of the Weight Loss Drug Manufacturers segment are excluded. Within a given segment each constituent is weighted according to its float -adjusted market cap. Each constituent is additionally capped as follows: Weight Loss Drug Manufacturer companies in the commercial stage are capped at 15%, Weight Loss Drug Manufacturer companies with a drug in the phase 3 stage are capped at 8%, Weight Loss Drug Manufacturer companies with a drug in the phase 2 stage or lower stage are capped at 5%, Combination Therapies Drug Manufacturer and Telehealth Providers are capped at 5%, and the sum of all constituent weights greater than 5% must be less than or equal to 45% of the Index.
Capped weights are redistributed to the constituents within the given segment. The Index is reconstituted and rebalanced quarterly, after the close of business on the third Friday of each March, June, September and December. For each reconstitution of the Index, constituents are determined based on data as of the last business day in each of February, May, August and November. Prices for determining weights for rebalances of the Index are determined on the Thursday prior to the second Friday of each March, June, September, and December. As of September 30, 2025, the Index was comprised of 22 securities. See Additional Information About the Funds Strategies and Risks The Index below for additional information regarding the Index. Concentration and Diversification Status. The Fund is classified as non -diversified under the Investment Company Act of 1940, as amended (the 1940 Act).
The Fund will not concentrate its investments ( i.e. , invest more than 25% of the value of its total assets) in securities of issuers in any industry or group of identified industries, except to the extent the Index concentrates in an industry or group of identified industries. As of the date of this prospectus, Fund has significant exposure to companies in the health care sector.
THNR Holdings
Top 10 holdings of Amplify Weight Loss Drug & Treatment ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Novo Nordisk A/S | 9.76% |
| Eli Lilly & Co | 9.26% |
| Scholar Rock Holding Corp | 5.71% |
| Hims & Hers Health Inc | 5.57% |
| Viking Therapeutics Inc | 5.49% |
| AbbVie Inc | 5.20% |
| Arrowhead Pharmaceuticals Inc | 5.08% |
| Innovent Biologics Inc | 5.00% |
| Amgen Inc | 4.58% |
| Chugai Pharmaceutical Co Ltd | 4.57% |
THNR Portfolio Allocation
Asset-class allocation of Amplify Weight Loss Drug & Treatment ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 97.4% |
| Cash & Equivalents | 2.0% |
THNR Performance
Total returns for THNR (as of 2026-10-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 1.9% |
| 1 year | 15.2% |
| 3 years (annualised) | 2.0% |
THNR Risk Information
Risk metrics for THNR, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 14.4%
THNR Costs and Fees
THNR costs about $59 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.59%
- Gross expense ratio: 0.59%
- Portfolio turnover: 70%
- Brokerage commissions: 2.60 bps of average net assets (SEC N-CEN)
THNR Cashflows
Over the 12 months to 2026-06, Amplify Weight Loss Drug & Treatment ETF had net inflows of $991.61K, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-06 | $0 |
| 2026-05 | $0 |
| 2026-04 | $0 |
| 2026-03 | $0 |
| 2026-02 | $519.34K |
| 2026-01 | $1.03M |
THNR Debt Constituents
No individual debt constituents are reported in Amplify Weight Loss Drug & Treatment ETF's latest SEC N-PORT filing.
THNR Prospectus and SEC Filings
Official Amplify Weight Loss Drug & Treatment ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Related funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.